391 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Tuesday’s Close
BIOS BioScrip, Inc. $2.99 $382.86M Sell
Article Searches
Daré Bio up 154% on positive tamoxifen data https://seekingalpha.com/news/3443719-dare-bio-154-percent-positive-tamoxifen-data?source=feed_news_all Mar 18, 2019 - Thinly traded nano cap Daré Bioscience (DARE +154.3%) is up on a 525x explosion in volume in response to positive clinical data supporting the value proposition of its vaginally administered tamoxifen
BTIG likes Arcus Bio in premarket analyst action https://seekingalpha.com/news/3443584-btig-likes-arcus-bio-premarket-analyst-action?source=feed_news_all Mar 18, 2019 - Momenta Pharmaceuticals (NASDAQ:MNTA) initiated with Neutral rating at BTIG Research.Arcus Biosciences (NYSE:RCUS) initiated with Buy rating and $20 (71% upside) price target at BTIG.Exelixis (NASDAQ:
Mustang Bio reports FY results https://seekingalpha.com/news/3443543-mustang-bio-reports-fy-results?source=feed_news_all Mar 18, 2019 - Mustang Bio (NASDAQ:MBIO): FY GAAP EPS of -$1.14.Cash and cash equivalents of $16.5MPress Release
Bioscrip Inc (BIOS) Q4 2018 Earnings Conference Call Transcript https://www.fool.com/earnings/call-transcripts/2019/03/15/bioscrip-inc-bios-q4-2018-earnings-conference-call.aspx?source=iedfolrf0000001 Mar 15, 2019 - BIOS earnings call for the period ending December 31, 2018.
BioScrip, Inc. (BIOS) CEO Dan Greenleaf on Q4 2018 Results, and BioScrip and Option Care Merger Transaction (Transcript) https://seekingalpha.com/article/4249145-bioscrip-inc-bios-ceo-dan-greenleaf-q4-2018-results-bioscrip-option-care-merger-transaction?source=feed_sector_transcripts Mar 15, 2019 - BioScrip, Inc. (NASDAQ:BIOS) Q4 2018 Results and BioScrip, and Option Care Merger Transaction Conference Call March 15, 2019 09:00 AM ET Company Participants Kathryn Stalmack - SVP and General Counsel
Achieve Life Sciences and Karyopharm Therapeutics among healthcare gainers; Biocept and BioScrip among losers https://seekingalpha.com/news/3443283-achieve-life-sciences-karyopharm-therapeutics-among-healthcare-gainers-biocept-bioscrip-among?source=feed_news_all Mar 15, 2019 - Gainers: Soleno Therapeutics (NASDAQ:SLNO) +249%. Achieve Life Sciences (NASDAQ:ACHV) +42%. Catasys (NASDAQ:CATS) +23%. Karyopharm Therapeutics (NASDAQ:KPTI) +23%. PhaseBio Pharmaceuticals (NASDAQ:PHA
BioScrip, Inc. 2018 Q4 - Results - Earnings Call Slides https://seekingalpha.com/article/4249062-bioscrip-inc-2018-q4-results-earnings-call-slides?source=feed_all_articles Mar 15, 2019 - The following slide deck was published by BioScrip, Inc. in conjunction with their 2018 Q4 earnings call.
Marrone Bio Reports Q4 Earnings, Plans To Prioritize Cannabis Market http://feeds.benzinga.com/~r/benzinga/~3/1bBRbQCp3gM/marrone-bio-reports-q4-earnings-plans-to-prioritize-cannabis-market Mar 15, 2019 -

Crop protection and plant health solutions company Marrone Bio Innovations Inc (NASDAQ: MBII) reported financial results for the fourth quarter and full year Thursday.

The Davis, California-based company posted fourth-quarter revenue of $5.7 million, up by 72 percent on the year.

read more

Hemispherx Bio up 8% on Ampligen progress https://seekingalpha.com/news/3442310-hemispherx-bio-8-percent-ampligen-progress?source=feed_news_all Mar 13, 2019 - Nano cap Hemispherx Biopharma (HEB +7.5%) is up on more than triple normal volume following its update on its Ampligen programs. It plans to release additional updates on a quarterly basis.Multiple cl
Moleculin Bio up 8% premarket on potential accelerated review for Annamycin https://seekingalpha.com/news/3442262-moleculin-bio-8-percent-premarket-potential-accelerated-review-annamycin?source=feed_news_all Mar 13, 2019 - Thinly traded nano cap Moleculin Biotech (NASDAQ:MBRX) is up 8% premarket on average volume on the heels of its request for Fast Track status from the FDA related to Annamycin for relapsed/refractory

Pages: 123456...40

Page 1>

Related Companies

Name Exchange Price Mkt Cap
CIVI Civitas Solutions, Inc. NYSE $14.35 $519.89M
CCM Concord Medical Services Holdings Limited NYSE $3.499 $151.73M
PETS PetMed Express, Inc. NASDAQ $36.88 $762.88M
ADUS Addus HomeCare Corporation NASDAQ $68.95 $806.53M
KANG iKang Healthcare Group, Inc. NASDAQ $17.41 $1.21B
Sector: Health Care > Industry: Medical/Nursing Services
DeepLinks for BioScrip
BIOS - Google Finance https://www.google.com/finance?q=BIOS Industry related info and international coverage Summary News
BIOS - Bloomberg http://www.bloomberg.com/research/stocks/snapshot/snapshot.asp?ticker=BIOS Original news and commentary from Bloomberg Charts Financials with pensions Snapshot Earnings Transactions People Options